Orthofix Investor Presentation Deck

(1) Orthofix Q2 2023 Highlights Constant Currency is calculated by applying foreign currency rates applicable to the comparable, prior-year period to present the current period net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is commonly used by management to analyze net sales excluding the impact of changes in foreign currency rates. (2) The reasons for and nature of non-GAAP disclosures by the Company, descriptions of the adjustments used to calculate those non-GAAP financial measures, and reconciliations of those non-GAAP financial measures to the most comparable GAAP financial measure, are provided in the Company's press release issued and Current Report on Form 8-K filed on August 8, 2023. (3) See Appendix A for calculation of proforma Adjusted EBITDA and proforma Adjusted Gross Margin for each quarterly period of 2022. $187M Q2 2023 Revenue 58% Growth YoY at Constant Currency(¹) 7% Proforma Growth YoY at Constant Currency (2) $105M Q2 2023 Global Spinal Implants, Biologics and Enabling Technologies Revenue 5% Proforma Growth YoY at Constant Currency(2) $38M Cash & Cash Equivalents, 6/30/2023 $59M of outstanding credit facility borrowings ©2023 Orthofix Medical Inc. All rights reserved | 14 $53M Q2 2023 BGT Revenue 10% Growth YoY $29M Q2 2023 Global Orthopedics Revenue 5% Growth YoY at Constant Currency (2) $10M Adjusted EBITDA 47% Proforma Growth YoY(2)(3) 72% Adjusted Gross Margin(2) ORTHOFIX® SeaSpine

View entire presentation